Intellectual Property
MegaNano BioTech has exclusively licensed the dendritic vaccine platform
developed by Dr. Chuanhai Cao which has the following novelties:
– Using healthy donor’s blood instead of patient’s blood to generate the
therapeutic vaccine
– Using immature dendritic cell to generate the vaccine other than
matured dendritic cells vaccine
– Using killed and lyophilized antigen sensitized dendritic cell as vaccine to
open this cell-based treatment available to patients around the world
– This therapeutic vaccine applies to any antigen related diseases. It has
been tested for AD and PD treatment and is under testing for lung
cancer, malaria
Advantages of a Dendritic Vaccine
- Overcome aging related immune tolerance.
- Bridged innate immunity and acquired immunity to control overreaction to a vaccine.
- Dendritic cell vaccine has been used in clinical for years and has no significant adverse effects.
- Meganano Biotech’s vaccine has outperformed competitors by utilizing a heterologous source, without needing a clod chain, and providing a more powerful vaccine. It is also a more affordable treatment than those of close competitors.
- 00Days
- 00Hours
- 00Minutes
- 00Seconds
Alzheimer's Disease - Amyloid Beta and Aging (Pre-clinical study - Animal study completed)
Time to clinical trials
50%
Parkinson's Disease - Alpha Synuclein and Aging (Pre-clinical study - Animal study completed)
Web Designer
50%